TY - JOUR
T1 - Frequent expression of MAGE1 tumor antigens in bronchial epithelium of smokers without lung cancer
AU - Bhutani, Manisha
AU - Pathak, Ashutosh Kumar
AU - Tang, Hongli
AU - Fan, You H.
AU - Liu, Diane D.
AU - Jack Lee, J.
AU - Kurie, Jonathan
AU - Morice, Rodolfo C.
AU - Hong, Waun Ki
AU - Mao, Li
PY - 2011/1
Y1 - 2011/1
N2 - Melanoma antigens (MAGE) are frequently expressed in lung cancer and are promising targets of anti-cancer immunotherapy. Our preliminary data suggested that MAGE may be expressed during early lung carcinogenesis, raising the possibility of targeting MAGE as a lung cancer prevention strategy. The purpose of this study was to investigate MAGE activation patterns in the airways of chronic smokers without lung cancer. MAGE-A1, -A3 and -B2 gene expression was determined in bronchial brush cells from chronic former smokers without lung cancer by reverse transcription-PCR(RT-PCR). The results were correlated with clinical parameters. The 123 subjects had a median age of 57 years, a median of 40 pack-years smoking history, and had quit smoking for at least one year prior to enrollment. Among the subjects, 31(25%), 38 (31%), and 46 (37%) had detectable MAGE-A1, -A3 and -B2 expression, respectively, in their bronchial brush samples. Expression of MAGE-A1 and -B2 positively correlated with pack-years smoking history (P=0.03 and 0.03, respectively). The frequency of expression did not decrease despite a prolonged smoking cessation period. In conclusion, MAGE-A1, -A3 and -B2 genes are frequently expressed in the bronchial epithelial cells of chronic smokers without lung cancer, suggesting that chronic exposure to cigarette smoke activates these genes even before the malignant transformation of bronchial cells in susceptible individuals. Once activated, the expression persists despite long-term smoking cessation. These data support the targeting of MAGE as a novel lung cancer prevention strategy.
AB - Melanoma antigens (MAGE) are frequently expressed in lung cancer and are promising targets of anti-cancer immunotherapy. Our preliminary data suggested that MAGE may be expressed during early lung carcinogenesis, raising the possibility of targeting MAGE as a lung cancer prevention strategy. The purpose of this study was to investigate MAGE activation patterns in the airways of chronic smokers without lung cancer. MAGE-A1, -A3 and -B2 gene expression was determined in bronchial brush cells from chronic former smokers without lung cancer by reverse transcription-PCR(RT-PCR). The results were correlated with clinical parameters. The 123 subjects had a median age of 57 years, a median of 40 pack-years smoking history, and had quit smoking for at least one year prior to enrollment. Among the subjects, 31(25%), 38 (31%), and 46 (37%) had detectable MAGE-A1, -A3 and -B2 expression, respectively, in their bronchial brush samples. Expression of MAGE-A1 and -B2 positively correlated with pack-years smoking history (P=0.03 and 0.03, respectively). The frequency of expression did not decrease despite a prolonged smoking cessation period. In conclusion, MAGE-A1, -A3 and -B2 genes are frequently expressed in the bronchial epithelial cells of chronic smokers without lung cancer, suggesting that chronic exposure to cigarette smoke activates these genes even before the malignant transformation of bronchial cells in susceptible individuals. Once activated, the expression persists despite long-term smoking cessation. These data support the targeting of MAGE as a novel lung cancer prevention strategy.
KW - Airway
KW - Lung cancer
KW - Melanoma antigens
KW - Prevention
KW - Smokers
UR - http://www.scopus.com/inward/record.url?scp=78751639642&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78751639642&partnerID=8YFLogxK
U2 - 10.3892/etm.2010.176
DO - 10.3892/etm.2010.176
M3 - Article
C2 - 22977481
AN - SCOPUS:78751639642
SN - 1792-0981
VL - 2
SP - 137
EP - 142
JO - Experimental and Therapeutic Medicine
JF - Experimental and Therapeutic Medicine
IS - 1
ER -